Body composition as a predictor of chemotherapy-related toxicity in pancreatic cancer patients: A systematic review

Abstract

ObjectivesThe objective of this systematic review was to assess associations between quantitative body composition measures extracted from imaging examinations and chemotherapy-related toxicity in pancreatic cancer patients. A secondary objective was to evaluate the different definitions of sarcopenia across included studies.MethodsThis systematic review was conducted according to the PRISMA statement. A comprehensive literature search of three electronic databases was performed by two authors. For each eligible article, information was collected concerning the clinical setting; basic study; population characteristics; technical; body composition features evaluated; CA 19.9 tumor marker levels; chemotherapy drugs administered; toxicities (hematologic, nausea/vomiting, diarrhea, neuropathy, reduction of number of cycles, overall toxicity); association of body composition values with toxicities. The overall quality of the included studies was critically evaluated.ResultsAfter the initial retrieval of 1137 articles, the systematic review included 12 articles (1/12 in the neo-adjuvant setting; 2/12 in the adjuvant setting; 3/12 in the metastatic setting; 2/12 in the unresectable setting; the other 4/12 included more than one clinical setting). The number of patients included ranged between 17 and 251; mean/median age ranged between 63 and 77 years; the percentage of sarcopenic patients ranged between 23 and 76%. The most frequent body composition parameter evaluated was skeletal muscle index (11/12). Chemotherapy regimens included gemcitabine (as monotherapy or in combination with other drugs); FOLFIRINOX and S-1. Among the trials including gemcitabine, 2/9 demonstrated an association with toxicity, whereas 7/9 did not; among those including FOLFIRINOX, one demonstrated associated toxicity whereas the others did not. Altogether, 4/12 papers demonstrated an association between the body composition values and the development of chemotherapy-related toxicities.ConclusionsThere is a wide variability of results about the association of body composition and chemotherapy-related toxicity in PC patients. Furthermore, cut-off values to define sarcopenia in PC patients are not yet uniformly defined.Systematic Review Registrationhttps://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42022337753, identifier CRD42022337753.

Genome sequencing of 2000 canids by the Dog10K consortium advances the understanding of demography, genome function and architecture

“…SLC28A3 (previously CNT3) is a concentrative nucleoside transporter with many functions. While no high-impact coding variants are present in the Dog10K strict variant catalog, coding variation in the human SLC28A3 ortholog are known to influence the metabolism of gemcitabine [ 102 , 103 ], a drug used to treat solid tumors in human [ 104 ] and canine patients [ 105 , 106 ]. Outside of the clinic, one of the most interesting observations has been the SLC28A3 association with advanced maternal age in studies of the methylome [ 107 ].…”

Nutritional Interventions during Chemotherapy for Pancreatic Cancer: A Systematic Review of Prospective Studies

“…In particular, sarcopenia is related with an increased incidence of severe adverse reactions and treatment interruption [ 40 , 41 , 42 , 43 ]. In patients with pancreatic neoplasm, results are still not conclusive [ 44 ]. In our systematic review, only two studies analyzed the effect of nutritional intervention on CIT, but no significant correlation was found [ 25 , 27 ].…”

Is Computed-Tomography-Based Body Composition a Reliable Predictor of Chemotherapy-Related Toxicity in Pancreatic Cancer Patients?

“…Indeed, our group recently performed a systematic review of the available literature on this subject, essentially showing that the association between body composition and chemotherapy-related toxicity in PC is still uncertain [29]. A part of the problem may lie in the lack of a single, univocal definition of a measurable parameter to characterize this syndrome and thus to evaluate its impact-which brings difficulty in establishing a benchmark across studies.…”